Marta Simone

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9279389/publications.pdf

Version: 2024-02-01

430754 501076 35 869 18 28 h-index citations g-index papers 36 36 36 1380 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years. Multiple Sclerosis Journal, 2022, 28, 2137-2141.	1.4	3
2	Peripheral Iron Levels in Autism Spectrum Disorders vs. Other Neurodevelopmental Disorders: Preliminary Data. International Journal of Environmental Research and Public Health, 2022, 19, 4006.	1.2	10
3	Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset. Neurology, 2022, 98, e1626-e1636.	1.5	7
4	A Randomized Computer-Assisted Rehabilitation Trial of Attention in Pediatric Multiple Sclerosis: A Post Hoc Analysis. Brain Sciences, 2021, 11, 637.	1.1	2
5	Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. JAMA Neurology, 2021, 78, 726.	4.5	26
6	Autism Spectrum Disorder and Duchenne Muscular Dystrophy: A Clinical Case on the Potential Role of the Dystrophin in Autism Neurobiology. Journal of Clinical Medicine, 2021, 10, 4370.	1.0	3
7	B and T Immunoregulation: A New Insight of B Regulatory Lymphocytes in Autism Spectrum Disorder. Frontiers in Neuroscience, 2021, 15, 732611.	1.4	8
8	Serum Neurofilament Light Chain Levels and Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Acquired Demyelinating Syndromes. Frontiers in Neurology, 2021, 12, 754518.	1.1	5
9	Psychological impact of the SARS-CoV-2 pandemic in children with neurodevelopmental disorders and their families: evaluation before and during covid-19 outbreak among an Italian sample. Rivista Di Psichiatria, 2021, 56, 205-210.	0.6	11
10	Coping, stress and negative psychological outcomes in parents of children admitted to a pediatric neurorehabilitation care unit. European Journal of Physical and Rehabilitation Medicine, 2020, 55, 772-782.	1.1	7
11	Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Brain, 2020, 143, 3013-3024.	3.7	53
12	Integrated Analysis of microRNA and mRNA Expression Profiles: An Attempt to Disentangle the Complex Interaction Network in Attention Deficit Hyperactivity Disorder. Brain Sciences, 2019, 9, 288.	1.1	22
13	Association between miRNAs expression and cognitive performances of Pediatric Multiple Sclerosis patients: A pilot study. Brain and Behavior, 2019, 9, e01199.	1.0	26
14	Aging with multiple sclerosis: prevalence and profile of cognitive impairment. Neurological Sciences, 2019, 40, 1651-1657.	0.9	39
15	Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis. Scientific Reports, 2019, 9, 18074.	1.6	28
16	Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study. Multiple Sclerosis Journal, 2019, 25, 399-407.	1.4	38
17	Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: An Italian collaborative study. Multiple Sclerosis Journal, 2018, 24, 1234-1242.	1.4	33
18	Combined microRNA and mRNA expression analysis in pediatric multiple sclerosis: an integrated approach to uncover novel pathogenic mechanisms of the disease. Human Molecular Genetics, 2018, 27, 66-79.	1.4	65

#	Article	IF	Citations
19	KIF5A and ALS2 Variants in a Family With Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis. Frontiers in Neurology, 2018, 9, 1078.	1.1	12
20	Computer-assisted rehabilitation of attention in pediatric multiple sclerosis and ADHD patients: a pilot trial. BMC Neurology, 2018, 18, 82.	0.8	28
21	Non-Verbal Cognitive Abilities in Children and Adolescents Affected by Migraine and Tension-Type Headache: An Observational Study Using the Leiter-3. Frontiers in Neurology, 2018, 9, 78.	1.1	4
22	Prognostic indicators in pediatric clinically isolated syndrome. Annals of Neurology, 2017, 81, 729-739.	2.8	34
23	A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmartâ,,¢â€"the FUTURE study. Neurological Sciences, 2017, 38, 1999-2005.	0.9	15
24	Risk factors for the existence of attention deficit hyperactivity disorder symptoms in children with autism spectrum disorders. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 1559-1567.	1.0	14
25	Association between MRI structural features and cognitive measures in pediatric multiple sclerosis. , 2017, , .		0
26	History of multiple sclerosis in 2 successive pregnancies. Neurology, 2016, 87, 1360-1367.	1.5	16
27	Use of Disease-Modifying Therapies in Pediatric MS. Current Treatment Options in Neurology, 2016, 18, 36.	0.7	34
28	The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1741-1749.	1.4	32
29	Overlap Between Autism Spectrum Disorders and Attention Deficit Hyperactivity Disorder: Searching for Distinctive/Common Clinical Features. Autism Research, 2015, 8, 328-337.	2.1	122
30	Markers of neurodevelopmental impairments in amp; nbsp; early-onset psychosis. Neuropsychiatric Disease and Treatment, 2015, 11, 1793.	1.0	9
31	Prolactin variations during risperidone therapy in a sample of drug-naive children and adolescents. International Clinical Psychopharmacology, 2015, 30, 103-108.	0.9	21
32	Antibasal Ganglia Antibodies and Antistreptolysin O in Noncomorbid ADHD. Journal of Attention Disorders, 2015, 19, 965-970.	1.5	25
33	Autism spectrum disorders in XYY syndrome: two new cases and systematic review of the literature. European Journal of Pediatrics, 2014, 173, 277-283.	1.3	28
34	Neuropsychopathological comorbidities in learning disorders. BMC Neurology, 2013, 13, 198.	0.8	78
35	Cerebral venous thrombosis after lumbar puncture and intravenous high dose corticosteroids: A case report of a childhood multiple sclerosis. Brain and Development, 2013, 35, 602-605.	0.6	11